DK3678644T3 - Formuleringer af copanlisib - Google Patents

Formuleringer af copanlisib Download PDF

Info

Publication number: DK3678644T3
Authority: DK; Denmark
Prior art keywords: copanlisib; formulations
Prior art date: 2017-09-08

Application number

DK18762107.3T

Other languages

English (en)

Inventor

Julia Freundlieb

Tia Jacobs

Original Assignee

Bayer Pharma AG

Bayer Consumer Care Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-08

Filing date

2018-09-06

Publication date

2023-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63407234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3678644(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-12-15 Priority claimed from EP17207771.1A external-priority patent/EP3498266A1/en

2018-09-06 Application filed by Bayer Pharma AG, Bayer Consumer Care Ag filed Critical Bayer Pharma AG

2023-07-31 Application granted granted Critical

2023-07-31 Publication of DK3678644T3 publication Critical patent/DK3678644T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Luminescent Compositions (AREA)
Road Signs Or Road Markings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK18762107.3T 2017-09-08 2018-09-06 Formuleringer af copanlisib DK3678644T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP17190117		2017-09-08
EP17207771.1A EP3498266A1 (en)	2017-12-15	2017-12-15	Formulations of copanlisib
PCT/EP2018/073965 WO2019048527A1 (en)	2017-09-08	2018-09-06	COPANLISIB FORMULATIONS

Publications (1)

Publication Number	Publication Date
DK3678644T3 true DK3678644T3 (da)	2023-07-31

Family

ID=63407234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18762107.3T DK3678644T3 (da)	2017-09-08	2018-09-06	Formuleringer af copanlisib

Country Status (36)

Country	Link
US (1)	US20200281932A1 (da)
EP (1)	EP3678644B1 (da)
JP (2)	JP2020533292A (da)
KR (1)	KR20200052326A (da)
CN (1)	CN111278430A (da)
AU (1)	AU2018328812A1 (da)
BR (1)	BR112020004545A2 (da)
CA (1)	CA3074890A1 (da)
CL (1)	CL2020000584A1 (da)
CO (1)	CO2020002628A2 (da)
CR (1)	CR20200111A (da)
CU (1)	CU24607B1 (da)
DK (1)	DK3678644T3 (da)
DO (1)	DOP2020000054A (da)
ES (1)	ES2950663T3 (da)
FI (1)	FI3678644T3 (da)
GE (1)	GEP20237486B (da)
HR (1)	HRP20230612T1 (da)
HU (1)	HUE063178T2 (da)
IL (1)	IL272857B2 (da)
JO (1)	JOP20200053A1 (da)
LT (1)	LT3678644T (da)
MA (1)	MA50068B1 (da)
MX (1)	MX2020002633A (da)
NI (1)	NI202000019A (da)
PE (1)	PE20200958A1 (da)
PH (1)	PH12020500448A1 (da)
PL (1)	PL3678644T3 (da)
RS (1)	RS64316B1 (da)
SG (1)	SG11202001696QA (da)
SI (1)	SI3678644T1 (da)
TW (1)	TWI794288B (da)
UA (1)	UA126817C2 (da)
UY (1)	UY37868A (da)
WO (1)	WO2019048527A1 (da)
ZA (1)	ZA202002378B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3946547A4 (en)	2019-03-26	2023-01-18	Pocket Naloxone Corp.	DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
US11278709B1 (en)	2021-03-12	2022-03-22	Pocket Naloxone Corp.	Drug delivery device and methods for using same
EP4070785B1 (en) *	2021-04-06	2023-11-08	Synthon B.V.	Lyophilized composition of copanlisib salt
CN117414367A (zh) *	2022-08-09	2024-01-19	北京清华长庚医院	一种逆转仑伐替尼耐药的药物组合物及其用途
US20240100019A1 (en) *	2022-09-28	2024-03-28	Urogen Pharma Ltd.	Compositions comprising a thermoreversible hydrogel, and having an extended in-use period

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2042504E (pt)	2002-09-30	2011-09-07	Bayer Schering Pharma Ag	Derivados da azolepirimidina fundida
AR064106A1 (es)	2006-12-05	2009-03-11	Bayer Schering Pharma Ag	Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2508525A1 (en)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP3018127A1 (en)	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
MA43957A (fr) *	2016-02-01	2018-12-12	Bayer Pharma AG	Biomarqueurs de copanlisib
US20190382839A1 (en) *	2016-02-01	2019-12-19	Bayer Pharma Aktiengesellschaft	Copanlisib biomarkers

2018
- 2018-09-06 IL IL272857A patent/IL272857B2/en unknown
- 2018-09-06 SI SI201830943T patent/SI3678644T1/sl unknown
- 2018-09-06 ES ES18762107T patent/ES2950663T3/es active Active
- 2018-09-06 SG SG11202001696QA patent/SG11202001696QA/en unknown
- 2018-09-06 TW TW107131361A patent/TWI794288B/zh not_active IP Right Cessation
- 2018-09-06 PE PE2020000322A patent/PE20200958A1/es unknown
- 2018-09-06 BR BR112020004545-4A patent/BR112020004545A2/pt not_active Application Discontinuation
- 2018-09-06 PL PL18762107.3T patent/PL3678644T3/pl unknown
- 2018-09-06 KR KR1020207009732A patent/KR20200052326A/ko not_active Withdrawn
- 2018-09-06 RS RS20230535A patent/RS64316B1/sr unknown
- 2018-09-06 HR HRP20230612TT patent/HRP20230612T1/hr unknown
- 2018-09-06 MA MA50068A patent/MA50068B1/fr unknown
- 2018-09-06 GE GEAP201815306A patent/GEP20237486B/en unknown
- 2018-09-06 US US16/644,472 patent/US20200281932A1/en not_active Abandoned
- 2018-09-06 MX MX2020002633A patent/MX2020002633A/es unknown
- 2018-09-06 CU CU2020000017A patent/CU24607B1/es unknown
- 2018-09-06 AU AU2018328812A patent/AU2018328812A1/en not_active Abandoned
- 2018-09-06 JO JOP/2020/0053A patent/JOP20200053A1/ar unknown
- 2018-09-06 FI FIEP18762107.3T patent/FI3678644T3/fi active
- 2018-09-06 WO PCT/EP2018/073965 patent/WO2019048527A1/en not_active Ceased
- 2018-09-06 UA UAA202002130A patent/UA126817C2/uk unknown
- 2018-09-06 EP EP18762107.3A patent/EP3678644B1/en active Active
- 2018-09-06 JP JP2020513544A patent/JP2020533292A/ja active Pending
- 2018-09-06 LT LTEPPCT/EP2018/073965T patent/LT3678644T/lt unknown
- 2018-09-06 CR CR20200111A patent/CR20200111A/es unknown
- 2018-09-06 HU HUE18762107A patent/HUE063178T2/hu unknown
- 2018-09-06 CN CN201880072307.9A patent/CN111278430A/zh active Pending
- 2018-09-06 DK DK18762107.3T patent/DK3678644T3/da active
- 2018-09-06 CA CA3074890A patent/CA3074890A1/en active Pending
- 2018-09-07 UY UY0001037868A patent/UY37868A/es not_active Application Discontinuation
2020
- 2020-03-05 PH PH12020500448A patent/PH12020500448A1/en unknown
- 2020-03-06 NI NI202000019A patent/NI202000019A/es unknown
- 2020-03-06 CL CL2020000584A patent/CL2020000584A1/es unknown
- 2020-03-06 DO DO2020000054A patent/DOP2020000054A/es unknown
- 2020-03-09 CO CONC2020/0002628A patent/CO2020002628A2/es unknown
- 2020-05-04 ZA ZA2020/02378A patent/ZA202002378B/en unknown
2023
- 2023-03-07 JP JP2023034647A patent/JP2023071917A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CO2020002628A2 (es)	2020-04-01
TWI794288B (zh)	2023-03-01
NI202000019A (es)	2020-08-28
JOP20200053A1 (ar)	2020-03-08
CL2020000584A1 (es)	2020-08-21
SI3678644T1 (sl)	2023-08-31
IL272857B2 (en)	2024-03-01
ES2950663T3 (es)	2023-10-11
WO2019048527A1 (en)	2019-03-14
ZA202002378B (en)	2023-10-25
US20200281932A1 (en)	2020-09-10
PL3678644T3 (pl)	2023-09-11
PE20200958A1 (es)	2020-09-24
EP3678644B1 (en)	2023-05-03
LT3678644T (lt)	2023-06-26
CU20200017A7 (es)	2020-11-30
IL272857A (en)	2020-04-30
HRP20230612T1 (hr)	2023-09-29
CN111278430A (zh)	2020-06-12
JP2023071917A (ja)	2023-05-23
RS64316B1 (sr)	2023-08-31
TW201919636A (zh)	2019-06-01
HUE063178T2 (hu)	2023-12-28
CU24607B1 (es)	2022-06-06
IL272857B1 (en)	2023-11-01
PH12020500448A1 (en)	2021-02-08
SG11202001696QA (en)	2020-03-30
GEP20237486B (en)	2023-03-27
EP3678644A1 (en)	2020-07-15
MA50068B1 (fr)	2024-07-31
AU2018328812A1 (en)	2020-03-12
UY37868A (es)	2019-04-30
FI3678644T3 (fi)	2023-07-28
CA3074890A1 (en)	2019-03-14
CR20200111A (es)	2020-07-24
BR112020004545A2 (pt)	2020-09-08
JP2020533292A (ja)	2020-11-19
UA126817C2 (uk)	2023-02-08
DOP2020000054A (es)	2020-09-30
MA50068A (fr)	2021-06-02
KR20200052326A (ko)	2020-05-14
MX2020002633A (es)	2020-07-13

Publication	Publication Date	Title
IL268697A (en)	2019-10-31	Formulations
DK3509581T3 (da)	2023-01-09	Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3688162T3 (da)	2024-05-13	Formuleringer
DK3554240T3 (da)	2021-09-20	Kombinationer af aktive forbindelser
DK3512850T3 (da)	2023-07-03	Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da)	2020-11-09	Inhibitorer af menin-mll-interaktionen
DK3668851T3 (da)	2022-03-28	Fremgangsmåde til fremstilling af thiocarbonater
MA50657A (fr)	2020-08-05	Formulations de niraparib
DK3137169T3 (da)	2022-02-14	Hæmmere af lysin-specifik demethylase-1
DK3102555T3 (da)	2021-08-09	Sammensætninger af forbindelser og anvendelser deraf
DK3259349T3 (da)	2020-08-10	Dehydrogenase-katalyseret fremstilling af FDCA
DK3474822T3 (da)	2025-08-18	Formuleringer af brincidofovir
EP3688069A4 (en)	2021-07-07	SILICONE COMPOSITIONS
DK3798222T3 (da)	2023-12-11	Krystallinsk form af den frie base af lorlatinib
DK3285756T3 (da)	2023-05-08	Formuleringer af l-ornithinphenylacetat
DK3943070T3 (da)	2024-01-22	Langtidsvirkende formuleringer af bedaquilin
DK3457851T3 (da)	2021-09-20	Derivater af sobetirom
EP3364945C0 (en)	2024-12-04	SOLID FORMULATION
IL272851A (en)	2020-04-30	Methods of using dipivefrin
DK3697418T3 (da)	2024-10-07	Forbedrede formuleringer af bromocriptin
EP4234657C0 (en)	2025-07-02	Compositions
DK3678644T3 (da)	2023-07-31	Formuleringer af copanlisib
DK3297619T3 (da)	2022-08-15	Terapeutiske anvendelser af L-4-chlorkynurenin
DK3368044T3 (da)	2021-09-13	Behandling af hepatisk steatose-relateret oligo-ovulation
DK3310331T3 (da)	2021-01-11	Injicerbare farmaceutiske formuleringer af lefamulin